期刊
EMBO MOLECULAR MEDICINE
卷 10, 期 4, 页码 -出版社
WILEY
DOI: 10.15252/emmm.201707918
关键词
collagen receptor; colorectal cancer; invasion; targeted therapy; tyrosine kinase
资金
- ARC
- Montpellier SIRIC Grant [INCa-DGOS-Inserm 6045]
- Ligue Nationale contre le Cancer
- CNRS
- University of Montpellier
- Montpellier SIRIC
- Fondation pour la Recherche Medicale
- INSERM
- Fondation de France
The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. Here, we show that nilotinib, a clinically approved drug for chronic myeloid leukaemia, strongly inhibits human CRC cell invasion invitro and reduces their metastatic potential in intrasplenic tumour mouse models. Nilotinib acts by inhibiting the kinase activity of DDR1, a receptor tyrosine kinase for collagens, which we identified as a RAS-independent inducer of CRC metastasis. Using quantitative phosphoproteomics, we identified BCR as a new DDR1 substrate and demonstrated that nilotinib prevents DDR1-mediated BCR phosphorylation on Tyr177, which is important for maintaining -catenin transcriptional activity necessary for tumour cell invasion. DDR1 kinase inhibition also reduced the invasion of patient-derived metastatic and circulating CRC cell lines. Collectively, our results indicate that the targeting DDR1 kinase activity with nilotinib may be beneficial for patients with mCRC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据